JM
Therapeutic Areas
Esperion Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NEXLETOL (bempedoic acid) | LDL-C lowering in HeFH/ASCVD | Phase 4 |
| NEXLIZET (bempedoic acid/ezetimibe) | LDL-C lowering in HeFH/ASCVD | Phase 4 |
| Bempedoic Acid | Cardiovascular Outcomes (Primary Prevention) | Phase 3 |
| Next-Gen FDCs | Comprehensive Lipid Management | Discovery |
Leadership Team at Esperion Therapeutics
SL
Sheldon L. Koenig
President and Chief Executive Officer
MA
Mark A. Glickman
Senior Vice President, Chief Financial Officer and Treasurer
BJ
Benjamin J. Quirk
Senior Vice President, General Counsel and Corporate Secretary
TM
Timothy M. Mayleben
Executive Advisor, Former CEO